PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02158221 |
Recruitment Status :
Completed
First Posted : June 6, 2014
Last Update Posted : February 10, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Migraine Without Aura | Drug: PACAP | Not Applicable |
Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of this genetic variant in humans are yet unknown.
PACAP is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. PACAP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks.
The phenotype of the migraine inducing effects of PACAP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Official Title: | PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load |
Study Start Date : | June 2014 |
Actual Primary Completion Date : | November 2014 |
Actual Study Completion Date : | December 2014 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Migraine patients with high genetic load
PACAP intravenous infusion 1.5 microgram/min for 20 min
|
Drug: PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Other Name: Pituitary adenylate cyclase-activating polypeptide |
Active Comparator: Migraine patients with low genetic load
PACAP intravenous infusion 1.5 microgram/min for 20 min
|
Drug: PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Other Name: Pituitary adenylate cyclase-activating polypeptide |
- Incidence of migraine attacks induced by PACAP in patients with high and low genetic load. [ Time Frame: Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP ]The difference in incidence of migraine-like attacks after PACAP between patients with and without high genetic load and patients with low genetic load using verbal rating scale (VRS).
- Incidence of headache induced by PACAP in patients with high and low genetic load. [ Time Frame: Change from baseline in headache intensity at 12 hours after the start of infusion of PACAP ]The difference in area under the curve (AUC) for headache intensity scores (0-12 hours) after infusion of PACAP
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine.
Exclusion Criteria:
- Other primary headache
- A history of cerebrovascular disease and other CNS- disease
- A history suggesting ischaemic heart disease
- Serious somatic and mental disease
- Hypo- or hypertension
- Abuse of alcohol or medicine (opioid analgesics).
- Pregnant or breastfeeding women.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02158221
Denmark | |
Danish Headache Center & Department of Neurology | |
Copenhagen, Glostrup, Denmark, 2600 |
Responsible Party: | Song Guo, MD, Danish Headache Center |
ClinicalTrials.gov Identifier: | NCT02158221 |
Other Study ID Numbers: |
H-2-2013-043 |
First Posted: | June 6, 2014 Key Record Dates |
Last Update Posted: | February 10, 2015 |
Last Verified: | February 2015 |
Migraine Disorders Migraine without Aura Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Pituitary Adenylate Cyclase-Activating Polypeptide Growth Substances Physiological Effects of Drugs Vasodilator Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |